Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Matthews

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics|January 30, 2009
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancerJames W Denham, Mahesh Kumar, Paul S Gleeson, et al.
Histopathology|April 15, 2020
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR TrialBrett Delahunt, Judith D Murray, Allison Steigler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology|November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham, Chantelle Wilcox, David Joseph, et al.
Environmental Research|August 2, 2017
Natural Assurance Scheme: A level playing field framework for Green-Grey infrastructure developmentBenjamin Denjean, Mónica A Altamirano, Nina Graveline, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trialJames W Denham, Allison Steigler, David S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 18, 2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancerDavid S Lamb, James W Denham, Hedy Mameghan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 28, 2008
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trialAnne Capp, Mario Inostroza-Ponta, Dana Bill, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
International Journal of Radiation Oncology, Biology, Physics|January 30, 2009
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancerJames W Denham, Mahesh Kumar, Paul S Gleeson, et al.
Histopathology|April 15, 2020
Perineural invasion by prostate adenocarcinoma in needle biopsies predicts bone metastasis: Ten year data from the TROG 03.04 RADAR TrialBrett Delahunt, Judith D Murray, Allison Steigler, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 7, 2012
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham, Chantelle Wilcox, David S Lamb, et al.
The Lancet. Oncology|November 16, 2012
Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham, Chantelle Wilcox, David Joseph, et al.
Environmental Research|August 2, 2017
Natural Assurance Scheme: A level playing field framework for Green-Grey infrastructure developmentBenjamin Denjean, Mónica A Altamirano, Nina Graveline, et al.
The Lancet. Oncology|December 24, 2018
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|August 19, 2014
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trialJames W Denham, David Joseph, David S Lamb, et al.
The Lancet. Oncology|November 1, 2005
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trialJames W Denham, Allison Steigler, David S Lamb, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 18, 2003
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancerDavid S Lamb, James W Denham, Hedy Mameghan, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 28, 2008
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trialAnne Capp, Mario Inostroza-Ponta, Dana Bill, et al.
Pageof 9